Original BioMedicals Co., Ltd. (6483.TWO)
Taipei Exchange · TWD · Healthcare · Drug Manufacturers - Specialty & Generic
NT$14.25 (+2.15%) as of
Key statistics
- Market cap
- 952.01M
- EPS (TTM)
- -1.53
- Dividend yield
- 0.00%
- 52-week range
- 9.12 – 20.00
- Beta
- 0.24
- Profit margin
- 0.00%
- Volume
- 558.91k
About Original BioMedicals Co., Ltd.
Original BioMedicals Co., Ltd. engages in the development of drugs in Taiwan. The company develops OBM-A01, a radiation injury prevention and therapeutic drug for the treatment of acute radiation injuries, including nuclear radiation and solar radiation exposure in space; OBM-B01, a cyanide compound drug for protection against toxic gases from fires; CCM-CL, a cyclic polypeptide antibiotic; and Iron Dextran, an injection for the treatment of iron deficiency. It also provides NE (vitamin C+E) and NE Butorphanol, as well as technical services. Original BioMedicals Co., Ltd. was incorporated in 2011 and is based in Tainan City, Taiwan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Tainan City, Taiwan
- Employees
- 25
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.